Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose and Food Effect Study of PORT-77 Administered Orally to Healthy Adult Participants

NCT06346509 is registered in ClinicalTrials.gov with Portal Therapeutics, Inc. as lead sponsor.

NCT NCT06346509
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06346509 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose and Food Effect Study of PORT-77 Administered Orally to Healthy Adult Participants
Lead sponsor
Portal Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
April 8, 2024
Completion date
January 20, 2026
Enrollment
156 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy adult participants